

# Scott E Eggener

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5147338/publications.pdf>

Version: 2024-02-01

231  
papers

13,184  
citations

23567

58  
h-index

24982

109  
g-index

237  
all docs

237  
docs citations

237  
times ranked

12149  
citing authors

#	ARTICLE	IF	CITATIONS
1	MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. <i>New England Journal of Medicine</i> , 2018, 378, 1767-1777.	27.0	2,036
2	Predicting 15-Year Prostate Cancer Specific Mortality After Radical Prostatectomy. <i>Journal of Urology</i> , 2011, 185, 869-875.	0.4	574
3	Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate: Recommendations from an International Working Group. <i>European Urology</i> , 2013, 64, 544-552.	1.9	383
4	Focal Therapy for Localized Prostate Cancer: A Critical Appraisal of Rationale and Modalities. <i>Journal of Urology</i> , 2007, 178, 2260-2267.	0.4	317
5	The Role of SPINK1 in ETS Rearrangement-Negative Prostate Cancers. <i>Cancer Cell</i> , 2008, 13, 519-528.	16.8	303
6	Positive Surgical Margins at Partial Nephrectomy: Predictors and Oncological Outcomes. <i>Journal of Urology</i> , 2008, 179, 2158-2163.	0.4	260
7	Renal Cell Carcinoma Recurrence After Nephrectomy for Localized Disease: Predicting Survival From Time of Recurrence. <i>Journal of Clinical Oncology</i> , 2006, 24, 3101-3106.	1.6	251
8	Pathological Upgrading and Up Staging With Immediate Repeat Biopsy in Patients Eligible for Active Surveillance. <i>Journal of Urology</i> , 2008, 180, 1964-1968.	0.4	247
9	New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. <i>European Urology</i> , 2017, 71, 17-34.	1.9	232
10	Quantitative Analysis of Multiparametric Prostate MR Images: Differentiation between Prostate Cancer and Normal Tissue and Correlation with Gleason Score—A Computer-aided Diagnosis Development Study. <i>Radiology</i> , 2013, 267, 787-796.	7.3	229
11	Diffusion-Weighted and Dynamic Contrast-Enhanced MRI of Prostate Cancer: Correlation of Quantitative MR Parameters With Gleason Score and Tumor Angiogenesis. <i>American Journal of Roentgenology</i> , 2011, 197, 1382-1390.	2.2	221
12	Focal Therapy: Patients, Interventions, and Outcomes—A Report from a Consensus Meeting. <i>European Urology</i> , 2015, 67, 771-777.	1.9	206
13	Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. <i>BJU International</i> , 2011, 108, 701-705.	2.5	195
14	National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening. <i>Journal of Clinical Oncology</i> , 2015, 33, 2416-2423.	1.6	184
15	Focal Therapy in Prostate Cancer: International Multidisciplinary Consensus on Trial Design. <i>European Urology</i> , 2014, 65, 1078-1083.	1.9	180
16	MR Imaging-guided Focal Laser Ablation for Prostate Cancer: Phase I Trial. <i>Radiology</i> , 2013, 267, 932-940.	7.3	178
17	Secondary Therapy, Metastatic Progression, and Cancer-Specific Mortality in Men with Clinically High-Risk Prostate Cancer Treated with Radical Prostatectomy. <i>European Urology</i> , 2008, 53, 950-959.	1.9	174
18	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. <i>Journal of Clinical Oncology</i> , 2020, 38, 2798-2811.	1.6	170

#	ARTICLE	IF	CITATIONS
19	Genomic Predictors of Outcome in Prostate Cancer. <i>European Urology</i> , 2015, 68, 1033-1044.	1.9	166
20	Robotic Radical Prostatectomy in Overweight and Obese Patients: Oncological and Validated-Functional Outcomes. <i>Urology</i> , 2009, 73, 316-322.	1.0	163
21	Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. <i>Journal of Urology</i> , 2019, 202, 272-281.	0.4	157
22	SPOP Promotes Tumorigenesis by Acting as a Key Regulatory Hub in Kidney Cancer. <i>Cancer Cell</i> , 2014, 25, 455-468.	16.8	154
23	Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer. <i>Journal of Urology</i> , 2020, 203, 706-712.	0.4	152
24	Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 1474-1494.	1.6	141
25	Use of social media in urology: data from the <scp>A</scp>merican <scp>U</scp>rological <scp>A</scp>ssociation (<scp>AUA</scp>). <i>BJU International</i> , 2014, 113, 993-998.	2.5	135
26	Global Trends in Testicular Cancer Incidence and Mortality. <i>European Urology</i> , 2011, 60, 374-379.	1.9	134
27	Incidence of Metastatic Nonseminomatous Germ Cell Tumor Outside the Boundaries of a Modified Postchemotherapy Retroperitoneal Lymph Node Dissection. <i>Journal of Clinical Oncology</i> , 2007, 25, 4365-4369.	1.6	132
28	Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. <i>World Journal of Urology</i> , 2015, 33, 623-631.	2.2	131
29	The Role of Robot-assisted Radical Prostatectomy and Pelvic Lymph Node Dissection in the Management of High-risk Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2014, 65, 918-927.	1.9	127
30	A Multi-Institutional Evaluation of Active Surveillance for Low Risk Prostate Cancer. <i>Journal of Urology</i> , 2009, 181, 1635-1641.	0.4	121
31	Testicular Cancer. <i>Medical Clinics of North America</i> , 2018, 102, 251-264.	2.5	120
32	Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy. <i>American Journal of Surgical Pathology</i> , 2016, 40, 1400-1406.	3.7	117
33	Phase II Evaluation of Magnetic Resonance Imaging Guided Focal Laser Ablation of Prostate Cancer. <i>Journal of Urology</i> , 2016, 196, 1670-1675.	0.4	116
34	Effect of Depression on Diagnosis, Treatment, and Mortality of Men With Clinically Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 2471-2478.	1.6	115
35	Clinical Outcome and Predictors of Survival in Late Relapse of Germ Cell Tumor. <i>Journal of Clinical Oncology</i> , 2008, 26, 5524-5529.	1.6	107
36	Chronic Kidney Disease Before and After Partial Nephrectomy. <i>Journal of Urology</i> , 2011, 185, 43-48.	0.4	105

#	ARTICLE	IF	CITATIONS
37	Population-Based Patterns and Predictors of Prostate-Specific Antigen Screening Among Older Men in the United States. <i>Journal of Clinical Oncology</i> , 2011, 29, 1736-1743.	1.6	100
38	Incidence of Disease Outside Modified Retroperitoneal Lymph Node Dissection Templates in Clinical Stage I or IIA Nonseminomatous Germ Cell Testicular Cancer. <i>Journal of Urology</i> , 2007, 177, 937-943.	0.4	97
39	Focal Therapy for Prostate Cancer: Possibilities and Limitations. <i>European Urology</i> , 2010, 58, 57-64.	1.9	95
40	Seminal Vesicle Invasion in Prostate Cancer: Evaluation by Using Multiparametric Endorectal MR Imaging. <i>Radiology</i> , 2013, 267, 797-806.	7.3	90
41	Temporary Renal Ischemia During Nephron Sparing Surgery is Associated With Short-Term but Not Long-Term Impairment in Renal Function. <i>Journal of Urology</i> , 2006, 176, 1339-1343.	0.4	89
42	Survival rates after resection for localized kidney cancer: 1989 to 2004. <i>Cancer</i> , 2008, 113, 84-96.	4.1	85
43	Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. <i>European Urology</i> , 2017, 71, 476-482.	1.9	85
44	National Trends in the Management of Low and Intermediate Risk Prostate Cancer in the United States. <i>Journal of Urology</i> , 2015, 193, 95-102.	0.4	84
45	Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 904-908.	1.6	80
46	Imaging-guided Prostate Biopsy: Conventional and Emerging Techniques. <i>Radiographics</i> , 2012, 32, 819-837.	3.3	77
47	Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel. <i>BJU International</i> , 2012, 110, 942-948.	2.5	77
48	Do Margins Matter? The Influence of Positive Surgical Margins on Prostate Cancerâ€™s Specific Mortality. <i>European Urology</i> , 2014, 65, 675-680.	1.9	77
49	African-American Prostate Cancer Disparities. <i>Current Urology Reports</i> , 2017, 18, 81.	2.2	77
50	Association of Cysteine-Rich Secretory Protein 3 and Î²2-Microseminoprotein with Outcome after Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2007, 13, 4130-4138.	7.0	76
51	High-Grade Ureteroscopic Biopsy Is Associated with Advanced Pathology of Upper-Tract Urothelial Carcinoma Tumors at Definitive Surgical Resection. <i>Journal of Endourology</i> , 2012, 26, 398-402.	2.1	75
52	Gleason 6 Prostate Cancer: Translating Biology into Population Health. <i>Journal of Urology</i> , 2015, 194, 626-634.	0.4	75
53	Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. <i>Cancer</i> , 2007, 109, 528-535.	4.1	73
54	Validation of Quantitative Analysis of Multiparametric Prostate MR Images for Prostate Cancer Detection and Aggressiveness Assessment: A Cross-Imager Study. <i>Radiology</i> , 2014, 271, 461-471.	7.3	72

#	ARTICLE	IF	CITATIONS
55	Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. American Journal of Transplantation, 2021, 21, 460-474.	4.7	67
56	Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer, 2013, 119, 3992-4002.	4.1	66
57	National trends in prostate cancer screening among older American men with limited 9-year life expectancies: Evidence of an increased need for shared decision making. Cancer, 2014, 120, 1491-1498.	4.1	64
58	Expression profiles of human epididymis epithelial cells reveal the functional diversity of caput, corpus and cauda regions. Molecular Human Reproduction, 2016, 22, 69-82.	2.8	64
59	Timing Is Everything: Preclinical Evidence Supporting Simultaneous Rather Than Sequential Chemohormonal Therapy for Prostate Cancer. Clinical Cancer Research, 2005, 11, 4905-4911.	7.0	63
60	Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy. , 2019, 7, 66.		63
61	Warm ischemia less than 30 minutes is not necessarily safe during partial nephrectomy: Every minute matters. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 826-828.	1.6	58
62	Low-risk Prostate Cancer: Identification, Management, and Outcomes. European Urology, 2017, 72, 238-249.	1.9	55
63	Adherence to National Comprehensive Cancer Network® Guidelines for Testicular Cancer. Journal of Urology, 2017, 197, 684-689.	0.4	52
64	The Natural History of Noncastrate Metastatic Prostate Cancer after Radical Prostatectomy. European Urology, 2007, 51, 940-948.	1.9	51
65	Apparent Diffusion Coefficient for Prostate Cancer Imaging: Impact of b Values. American Journal of Roentgenology, 2014, 202, W247-W253.	2.2	51
66	Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease. Urology, 2005, 66, 156-160.	1.0	50
67	2008 US Preventive Services Task Force Recommendations and Prostate Cancer Screening Rates. JAMA - Journal of the American Medical Association, 2012, 307, 1692.	7.4	50
68	Knotless Closure of the Collecting System and Renal Parenchyma with a Novel Barbed Suture During Laparoscopic Porcine Partial Nephrectomy. Journal of Endourology, 2009, 23, 1157-1160.	2.1	48
69	Suppressive Roles of Calreticulin in Prostate Cancer Growth and Metastasis. American Journal of Pathology, 2009, 175, 882-890.	3.8	47
70	The Total Number of Retroperitoneal Lymph Nodes Resected Impacts Clinical Outcome After Chemotherapy for Metastatic Testicular Cancer. Urology, 2010, 75, 1431-1435.	1.0	47
71	Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7), Tj ETQq1 1 0.784314 rgBT /Overlock 10 T Stratification: A Systematic Review. European Urology Focus, 2017, 3, 487-497.	3.1	46
72	Comparison of T2-Weighted Imaging, DWI, and Dynamic Contrast-Enhanced MRI for Calculation of Prostate Cancer Index Lesion Volume: Correlation With Whole-Mount Pathology. American Journal of Roentgenology, 2019, 212, 351-356.	2.2	46

#	ARTICLE	IF	CITATIONS
73	Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. <i>American Journal of Transplantation</i> , 2021, 21, 475-483.	4.7	45
74	Laser ablation as focal therapy for prostate cancer. <i>Current Opinion in Urology</i> , 2014, 24, 236-240.	1.8	42
75	Low-Grade Prostate Cancer: Time to Stop Calling It Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3110-3114.	1.6	41
76	Anatomy of the Rectourethralis Muscle. <i>European Urology</i> , 2002, 41, 94-100.	1.9	38
77	Relationship of Prostate-Specific Antigen Velocity to Histologic Findings in a Prostate Cancer Screening Program. <i>Urology</i> , 2008, 71, 1016-1019.	1.0	36
78	A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility. <i>Urology</i> , 2019, 126, 76-82.	1.0	36
79	Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis. <i>European Urology</i> , 2021, 79, 419-426.	1.9	36
80	Expression, Function of the Human Androgen-Responsive Gene AD11 in Prostate Cancer. <i>Neoplasia</i> , 2007, 9, 643-651.	5.3	35
81	The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. <i>Future Oncology</i> , 2019, 15, 1683-1695.	2.4	35
82	Ablation energies for focal treatment of prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 409-418.	2.2	34
83	Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model. <i>Prostate</i> , 2006, 66, 495-502.	2.3	32
84	Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. <i>European Urology</i> , 2022, 82, 341-351.	1.9	32
85	Prostate Volumes Derived From MRI and Volume-Adjusted Serum Prostate-Specific Antigen: Correlation With Gleason Score of Prostate Cancer. <i>American Journal of Roentgenology</i> , 2013, 201, 1041-1048.	2.2	31
86	Critical Evaluation of Modified Templates and Current Trends in Retroperitoneal Lymph Node Dissection. <i>Current Urology Reports</i> , 2013, 14, 511-517.	2.2	30
87	Retroperitoneal lymph node dissection: reassessment of modified templates. <i>BJU International</i> , 2009, 104, 1369-1375.	2.5	29
88	Local staging of prostate cancer with MRI. <i>Diagnostic and Interventional Radiology</i> , 2011, 18, 365-73.	1.5	29
89	Patient selection for focal therapy of localized prostate cancer. <i>Current Opinion in Urology</i> , 2009, 19, 268-273.	1.8	28
90	Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer. <i>European Urology</i> , 2017, 72, 455-460.	1.9	28

#	ARTICLE	IF	CITATIONS
91	The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. <i>European Urology</i> , 2019, 76, 268-272.	1.9	28
92	Radical Prostatectomy Shortly After Prostate Biopsy Does Not Affect Operative Difficulty or Efficacy. <i>Urology</i> , 2007, 69, 1128-1133.	1.0	27
93	Laparoscopic Partial Nephrectomy: A Single-center Evolving Experience. <i>Urology</i> , 2010, 75, 282-287.	1.0	27
94	Prostate Cancer Screening. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 825.	7.4	27
95	A Single Microfocus (5% or Less) of Gleason 6 Prostate Cancer at Biopsy—Can We Predict Adverse Pathological Outcomes?. <i>Journal of Urology</i> , 2008, 180, 2436-2440.	0.4	26
96	Focal Treatment of Prostate Cancer with Vascular-Targeted Photodynamic Therapy. <i>Scientific World Journal, The</i> , 2008, 8, 963-973.	2.1	26
97	Contemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate. <i>Urology</i> , 2015, 86, 777-782.	1.0	26
98	Pathologic outcomes for low-risk prostate cancer after delayed radical prostatectomy in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 164.e11-164.e17.	1.6	26
99	Predominantly cystic clear cell renal cell carcinoma and multilocular cystic renal neoplasm of low malignant potential form a low-grade spectrum. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 85-93.	2.8	26
100	Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance. <i>European Urology</i> , 2014, 66, 611-612.	1.9	25
101	Characterization of primary cultures of adult human epididymis epithelial cells. <i>Fertility and Sterility</i> , 2015, 103, 647-654.e1.	1.0	25
102	Perioperative clinical thromboembolic events after radical or partial nephrectomy. <i>Urology</i> , 2006, 68, 988-992.	1.0	24
103	Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery. <i>World Journal of Urology</i> , 2016, 34, 687-693.	2.2	24
104	Management trends for men with early-stage nonseminomatous germ cell tumors of the testicle: An analysis of the National Cancer Database. <i>Cancer</i> , 2017, 123, 245-252.	4.1	24
105	Long-term survival after drop metastases of renal cell carcinoma to the bladder. <i>Urology</i> , 2002, 60, 697.	1.0	23
106	Dynamic Contrast-enhanced MR Imaging Features of the Normal Central Zone of the Prostate. <i>Academic Radiology</i> , 2014, 21, 569-577.	2.5	23
107	Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 847-854.	6.3	23
108	Short (≤1mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy. <i>BJU International</i> , 2013, 111, 559-563.	2.5	22



#	ARTICLE	IF	CITATIONS
109	Empiric antibiotics for an elevated prostate-specific antigen (<scp>PSA</scp>) level: a randomised, prospective, controlled multi-institutional trial. <i>BJU International</i> , 2013, 112, 925-929.	2.5	22
110	The Volume of Nonneoplastic Parenchyma in a Minimally Invasive Partial Nephrectomy Specimen: Predictive Factors and Impact on Renal Function. <i>Journal of Endourology</i> , 2014, 28, 196-200.	2.1	22
111	Clinical and Histologic Predictors of Renal Function Decline After Laparoscopic Partial Nephrectomy. <i>Journal of Endourology</i> , 2011, 25, 1435-1441.	2.1	20
112	Intensity modulated radiation therapy after radical prostatectomy: Early results show no decline in urinary continence, gastrointestinal, or sexual quality of life. <i>Practical Radiation Oncology</i> , 2013, 3, 138-144.	2.1	19
113	Feasibility of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using Low-Dose Gadolinium. <i>Investigative Radiology</i> , 2018, 53, 609-615.	6.2	19
114	No Effect of Music on Anxiety and Pain During Transrectal Prostate Biopsies: A Randomized Trial. <i>Urology</i> , 2018, 117, 31-35.	1.0	19
115	A novel transcriptional network for the androgen receptor in human epididymis epithelial cells. <i>Molecular Human Reproduction</i> , 2018, 24, 433-443.	2.8	19
116	Prediagnosis Prostate Specific Antigen Velocity is Associated With Risk of Prostate Cancer Progression Following Brachytherapy and External Beam Radiation Therapy. <i>Journal of Urology</i> , 2006, 176, 1399-1403.	0.4	18
117	Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy. <i>European Urology</i> , 2019, 76, 686-692.	1.9	18
118	Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: Early results. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 465-471.	1.6	17
119	Comparison of models to predict clinical failure after radical prostatectomy. <i>Cancer</i> , 2009, 115, 303-310.	4.1	17
120	Corneal Abrasion in Hysterectomy and Prostatectomy. <i>Anesthesiology</i> , 2015, 122, 994-1001.	2.5	17
121	High-resolution MRI of excised human prostate specimens acquired with 9.4T in detection and identification of cancers: Validation of a technique. <i>Journal of Magnetic Resonance Imaging</i> , 2011, 34, 956-961.	3.4	16
122	Environmental toxicology of testicular cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 212-215.	1.6	16
123	National Economic Conditions and Patient Insurance Status Predict Prostate Cancer Diagnosis Rates and Management Decisions. <i>Journal of Urology</i> , 2016, 195, 1383-1389.	0.4	16
124	HNF1 regulates critical processes in the human epididymis epithelium. <i>Molecular and Cellular Endocrinology</i> , 2016, 425, 94-102.	3.2	16
125	Region-specific microRNA signatures in the human epididymis. <i>Asian Journal of Andrology</i> , 2018, 20, 539.	1.6	16
126	Incidence, Risk Factors, and Outcomes for Rectal Injury During Radical Prostatectomy: A Population-based Study. <i>European Urology Oncology</i> , 2018, 1, 501-506.	5.4	16



#	ARTICLE	IF	CITATIONS
127	MRI Findings After MRI-Guided Focal Laser Ablation of Prostate Cancer. American Journal of Roentgenology, 2018, 211, 595-604.	2.2	16
128	Impact of warm versus cold ischemia on renal function following partial nephrectomy. World Journal of Urology, 2015, 33, 351-357.	2.2	15
129	Updated Survey of Social Media Use by Members of the American Urological Association. Urology Practice, 2015, 2, 138-143.	0.5	14
130	Risk of lymph node metastases in pathological gleason scoreâ%6 prostate adenocarcinoma: Analysis of institutional and population-based databases. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 31.e1-31.e6.	1.6	14
131	Diagnosis of Prostate Cancer by Use of MRI-Derived Quantitative Risk Maps: A Feasibility Study. American Journal of Roentgenology, 2019, 213, W66-W75.	2.2	14
132	Validation of Prostate Tissue Composition by Using Hybrid Multidimensional MRI: Correlation with Histologic Findings. Radiology, 2022, 302, 368-377.	7.3	14
133	Preoperative Nuclear Renal Scan Underestimates Renal Function After Radical Nephrectomy. Urology, 2014, 84, 1402-1407.	1.0	13
134	Robotic-assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes. World Journal of Urology, 2015, 33, 1689-1694.	2.2	13
135	Region-specific innate antiviral responses of the human epididymis. Molecular and Cellular Endocrinology, 2018, 473, 72-78.	3.2	13
136	Prostate Cancer and the Evolving Role of Biomarkers in Screening and Diagnosis. Radiologic Clinics of North America, 2018, 56, 187-196.	1.8	13
137	Clinical and Radiographic Predictors of Great Vessel Resection or Reconstruction During Retroperitoneal Lymph Node Dissection for Testicular Cancer. Urology, 2019, 123, 186-190.	1.0	13
138	The evolution, controversies, and potential pitfalls of modified retroperitoneal lymph node dissection templates. World Journal of Urology, 2009, 27, 477-483.	2.2	12
139	Commentary on: "Long-term functional outcomes after treatment for localized prostate cancer." Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF. Department of Urologic Surgery and the Center for Surgical Quality and Outcomes Research, Vanderbilt University, Nashville, TN.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 512-514.	1.6	12
140	Population Based Analysis of Incidence and Predictors of Open Conversion during Minimally Invasive Radical Prostatectomy. Journal of Urology, 2015, 193, 826-831.	0.4	12
141	Lymph node count impacts survival following postâchemotherapy retroperitoneal lymphadenectomy for nonâseminomatous testicular cancer: a populationâbased analysis. BJU International, 2019, 124, 792-800.	2.5	12
142	Multi-institution analysis of racial disparity among African-American men eligible for prostate cancer active surveillance. Oncotarget, 2018, 9, 21359-21365.	1.8	12
143	Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. World Journal of Urology, 2022, 40, 1505-1512.	2.2	12
144	Evaluation of tumor coverage after MRâguided prostate focal laser ablation therapy. Medical Physics, 2019, 46, 800-810.	3.0	11

#	ARTICLE	IF	CITATIONS
145	Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 172-178.	3.9	11
146	Should Grade Group 1 (GG1) be called cancer?. <i>World Journal of Urology</i> , 2022, 40, 15-19.	2.2	11
147	Juxtaglomerular apparatus tumor: a rare, surgically correctable cause of hypertension. <i>Reviews in Urology</i> , 2002, 4, 192-5.	0.9	11
148	The Impact of Body Mass Index on Renal Functional Outcomes Following Minimally Invasive Partial Nephrectomy. <i>Journal of Endourology</i> , 2014, 28, 1338-1344.	2.1	10
149	Prostate cancer detection following diagnosis of atypical small acinar proliferation. <i>Canadian Journal of Urology</i> , 2017, 24, 8714-8720.	0.0	10
150	Giant Multilocular Cystadenoma of the Prostate: AIRP Best Cases in Radiologic-Pathologic Correlation. <i>Radiographics</i> , 2015, 35, 1051-1055.	3.3	9
151	Bladder dose-volume parameters are associated with urinary incontinence after postoperative intensity modulated radiation therapy for prostate cancer. <i>Practical Radiation Oncology</i> , 2016, 6, e179-e185.	2.1	9
152	Prostate Cancer Screening Biomarkers: An Emerging Embarrassment of "Riches"? <i>European Urology</i> , 2016, 70, 54-55.	1.9	9
153	Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. <i>Cancer</i> , 2019, 125, 2965-2974.	4.1	9
154	Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle. <i>European Urology Oncology</i> , 2020, 3, 198-206.	5.4	9
155	Cleason 6 Prostate Cancer in One or Two Biopsy Cores Can Harbor More Aggressive Disease. <i>Journal of Endourology</i> , 2011, 25, 699-703.	2.1	8
156	Management of Low-Stage Testicular Seminoma. <i>Urologic Clinics of North America</i> , 2015, 42, 287-298.	1.8	8
157	Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 69.e29-69.e34.	1.6	8
158	Prediction of renal mass aggressiveness using clinical and radiographic features: a global, multicentre prospective study. <i>BJU International</i> , 2016, 117, 914-922.	2.5	8
159	The Impact of Perioperative Aspirin on Bleeding Complications Following Robotic Partial Nephrectomy. <i>Journal of Endourology</i> , 2016, 30, 997-1003.	2.1	8
160	The impact of days off between cases on perioperative outcomes for robotic-assisted laparoscopic prostatectomy. <i>World Journal of Urology</i> , 2016, 34, 269-274.	2.2	8
161	Influence of pathologist experience on positive surgical margins following radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 461.e1-461.e6.	1.6	8
162	Urology Residents' Experience and Attitude Toward Surgical Simulation: Presenting our 4-Year Experience With a Multi-institutional, Multi-modality Simulation Model. <i>Urology</i> , 2017, 109, 32-37.	1.0	8

#	ARTICLE	IF	CITATIONS
163	Commentary regarding a recent collaborative consensus statement addressing prostate MRI and MRI-targeted biopsy in patients with a prior negative prostate biopsy. <i>Abdominal Radiology</i> , 2017, 42, 346-349.	2.1	8
164	SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer. <i>Journal of Urology</i> , 2019, 202, 952-958.	0.4	8
165	Indications for adrenalectomy during radical nephrectomy for renal cancer. <i>Arab Journal of Urology Arab Association of Urology</i> , 2014, 12, 304-308.	1.5	7
166	Health technology assessment in evolution – focal therapy in localised prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1359-1367.	2.4	7
167	Novel focal therapy treatment options for prostate cancer. <i>Current Opinion in Urology</i> , 2018, 28, 178-183.	1.8	7
168	Tobacco and marijuana use and their association with serum prostate-specific antigen levels among African American men in Chicago. <i>Preventive Medicine Reports</i> , 2020, 20, 101174.	1.8	7
169	Effectiveness of Subcutaneously Administered Leuprolide Acetate to Achieve Low Nadir Testosterone in Prostate Cancer Patients. <i>Reviews in Urology</i> , 2018, 20, 63-68.	0.9	7
170	Urolithiasis associated with topiramate. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2004, 30, 29-31.	1.5	6
171	Editorial Comment on: Positive Surgical Margin Appears To Have Negligible Impact on Survival of Renal Cell Carcinomas Treated by Nephron-Sparing Surgery. <i>European Urology</i> , 2010, 57, 472.	1.9	6
172	Revisiting the central gland anatomy via MRI: Does the central gland extend below the level of verumontanum?. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 39, 167-171.	3.4	6
173	Indications, evolving technique, and early outcomes with robotic retroperitoneal lymph node dissection. <i>Current Opinion in Urology</i> , 2018, 28, 461-468.	1.8	6
174	Prostate Cancer. <i>Scientific World Journal, The</i> , 2011, 11, 749-750.	2.1	5
175	The challenging landscape of medical device approval in localized prostate cancer. <i>Nature Reviews Urology</i> , 2016, 13, 91-98.	3.8	5
176	Recurrence After Robotic Retroperitoneal Lymph Node Dissection Raises More Questions than Answers. <i>European Urology</i> , 2019, 76, 610-611.	1.9	5
177	Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging. <i>European Urology Oncology</i> , 2019, 2, 257-264.	5.4	5
178	Impact of Non-guideline-directed Care on Quality of Life in Testicular Cancer Survivors. <i>European Urology Focus</i> , 2020, 7, 1137-1142.	3.1	5
179	News from Clinical Research Office of the Endourological Society (CROES). <i>Journal of Endourology</i> , 2015, 29, 495-497.	2.1	4
180	Generalizability of Clinical Trials: Why It Matters for Patients and Public Policy. <i>European Urology</i> , 2017, 71, 515-516.	1.9	4

#	ARTICLE	IF	CITATIONS
181	Active surveillance monitoring: the role of novel biomarkers and imaging. Asian Journal of Andrology, 2015, 17, 882.	1.6	4
182	Editorial Comment for Seideman <i>et al.</i>. Journal of Endourology, 2011, 25, 1247-1248.	2.1	3
183	Commentary on "Repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare." Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM, Department of Urology, New York University, New York, NY.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 935-936.	1.6	3
184	Nerve Bundle Hydrodissection and Sexual Function after Robot Prostatectomy. Journal of the Society of Laparoendoscopic Surgeons, 2017, 21, e2017.00068.	1.1	3
185	Evaluation of Focal Laser Ablation of Prostate Cancer Using High Spectral and Spatial Resolution Imaging: A Pilot Study. Journal of Magnetic Resonance Imaging, 2019, 49, 1374-1380.	3.4	3
186	T2*-weighted MRI as a non-contrast-enhanced method for assessment of focal laser ablation zone extent in prostate cancer thermotherapy. European Radiology, 2021, 31, 325-332.	4.5	3
187	Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer. Journal of Urology, 2022, 207, 262-264.	0.4	3
188	Perspectives on International Urological Volunteerism: A Survey of IVUmed Resident Scholar Alumni. Urology Practice, 2017, 4, 176-182.	0.5	2
189	Diagnosis of non-neoplastic renal diseases in renal mass biopsies. Journal of Onco-Nephrology, 2019, 3, 49-52.	0.6	2
190	Recognizing and minimizing bias: Helping patients make their best choice for prostate cancer management through multidisciplinary clinics. Cancer, 2020, 126, 470-472.	4.1	2
191	Re: NCCN Prostate Cancer Guidelines Version 1.2022 " September 10, 2021. European Urology, 2022, 81, 218.	1.9	2
192	Focal therapy for clinically localized prostate cancer. Archivos Espanoles De Urologia, 2011, 64, 815-22.	0.2	2
193	Re: Do Adenocarcinomas of the Prostate with Gleason Score (GS) "6 Have the Potential to Metastasize to Lymph Nodes?. European Urology, 2013, 63, 960.	1.9	1
194	Commentary on "African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: Should active surveillance still be an option for them?" Sundi D, Ross AE, Humphreys EB, Han M, Partin AW, Carter HB, Schaeffer EM, Johns Hopkins University, Baltimore, MD.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 936.	1.6	1
195	MP53-04 SIGNIFICANT INTER-INSTITUTIONAL VARIATIONS IN RACIAL DISPARITIES AMONG AFRICAN-AMERICAN MEN ELIGIBLE FOR PROSTATE CANCER ACTIVE SURVEILLANCE. Journal of Urology, 2015, 193, .	0.4	1
196	How active should active surveillance be?. BJU International, 2015, 115, 176-177.	2.5	1
197	Patient-Initiated Prostate Cancer Screening Among Older U.S. Men. Annals of Internal Medicine, 2016, 164, 702.	3.9	1
198	Managing Cancer Relapse After Radical Prostatectomy. Urologic Clinics of North America, 2017, 44, 597-609.	1.8	1

#	ARTICLE	IF	CITATIONS
199	Nodal Metastases at Radical Prostatectomy: More Aggressive Disease Warrants Consideration of Multimodal Treatment. <i>European Urology</i> , 2018, 73, 897-898.	1.9	1
200	International and Multi-institutional Assessment of Factors Associated With Performance and Quality of Lymph Node Dissection During Radical Nephrectomy. <i>Urology</i> , 2019, 129, 132-138.	1.0	1
201	Re: Use of Active Surveillance or Watchful Waiting for Low-risk Prostate Cancer and Management Trends Across Risk Groups in the United States 2010-2015. <i>European Urology</i> , 2019, 76, 252.	1.9	1
202	Reply by Authors. <i>Journal of Urology</i> , 2021, 205, 779-779.	0.4	1
203	Editorial Comment. <i>Journal of Urology</i> , 2019, 201, 266-267.	0.4	1
204	Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup. <i>Journal of Urology</i> , 2022, 207, 1236-1245.	0.4	1
205	Radical Prostatectomy Without Biopsy: Audacious, Imprudent, or Innovative?. <i>European Urology</i> , 2022, 82, 161-162.	1.9	1
206	Editorial Comment on: Reducing Laparoscopic Radical Prostatectomy False-Positive Margin Rates Using Cyanoacrylate Tissue Glue. <i>European Urology</i> , 2009, 56, 658.	1.9	0
207	Editorial Comment on: Preservation of Lateral Prostatic Fascia is Associated with Urine Continence after Robotic-Assisted Prostatectomy. <i>European Urology</i> , 2009, 55, 900-901.	1.9	0
208	Editorial Comment on: Pharmacological Approaches to Reducing the Risk of Prostate Cancer. <i>European Urology</i> , 2009, 55, 1073-1074.	1.9	0
209	Editorial Comment on: Perioperative Morbidity of Laparoscopic Cryoablation of Small Renal Masses with Ultrathin Probes: A European Multicentre Experience. <i>European Urology</i> , 2009, 56, 361-362.	1.9	0
210	The clinical diversity of postchemotherapy germ cell teratoma. <i>Cancer</i> , 2009, 115, 1138-1141.	4.1	0
211	Elastographic search for the (high-grade) tree in the (prostatic) forest. <i>BJU International</i> , 2014, 113, 514-515.	2.5	0
212	Editorial Comment. <i>Journal of Urology</i> , 2014, 192, 81-81.	0.4	0
213	Known Knowns, Known Unknowns, and Unknown Unknowns of High-intensity Focused Ultrasound for Prostate Cancer. <i>European Urology Focus</i> , 2015, 1, 171-172.	3.1	0
214	Corneal Abrasion in Hysterectomy and Prostatectomy. <i>Survey of Anesthesiology</i> , 2016, 60, 25.	0.1	0
215	Editorial Comment. <i>Journal of Urology</i> , 2016, 196, 1668-1669.	0.4	0
216	Can Focal Treatment Replace Radical Treatment in Prostate Cancer? For Focal Therapy. <i>European Urology Focus</i> , 2017, 3, 522-523.	3.1	0

#	ARTICLE	IF	CITATIONS
217	“Real-world” Practice Makes Perfect: Ensuring the Active Component of Active Surveillance for Prostate Cancer. <i>European Urology</i> , 2018, 74, 708-709.	1.9	0
218	Late Relapse of Nonseminomatous Germ Cell Tumor 24 Years Later. <i>Urology</i> , 2018, 122, 16-18.	1.0	0
219	Obscenity, Michael Jordan, and Measuring Outcomes: Explaining and Improving the Quality of Kidney Cancer Care. <i>European Urology</i> , 2019, 75, 635-636.	1.9	0
220	An Unusual Case of Resistant Hypertension Secondary to Fibromuscular Dysplasia. <i>JACC: Case Reports</i> , 2020, 2, 2460-2464.	0.6	0
221	Prostate-specific Antigen to Predict Early Success of Focal Therapy: Focusing on Appropriate Endpoints. <i>European Urology</i> , 2020, 78, 161-162.	1.9	0
222	Re: Pretransplant Solid Organ Malignancy and Organ Transplant Candidacy: A Consensus Expert Opinion Statement. <i>European Urology</i> , 2021, 79, 552-553.	1.9	0
223	Editorial Comment. <i>Journal of Urology</i> , 2021, 206, 668-668.	0.4	0
224	719: Renal Cell Carcinoma Recurrence Following Nephrectomy for Localized Disease: Predicting Survival from Time of Recurrence. <i>Journal of Urology</i> , 2006, 175, 233-233.	0.4	0
225	Active surveillance for prostate cancer. <i>Translational Andrology and Urology</i> , 2018, 7, 195-196.	1.4	0
226	Reply by Authors. <i>Journal of Urology</i> , 2019, 202, 958-958.	0.4	0
227	Focal Therapy for Localized Prostate Cancer. <i>Reviews in Urology</i> , 2018, 20, 143-144.	0.9	0
228	Editorial comment on: Methods of calculating prostate-specific antigen velocity. <i>European Urology</i> , 2007, 52, 1050-1.	1.9	0
229	Re: Active surveillance failure for prostate cancer: does the delay in treatment increase the risk of urinary incontinence?. <i>Canadian Journal of Urology</i> , 2012, 19, 6292.	0.0	0
230	Pathological characteristics of the large renal mass: potential implication for clinical role of renal biopsy. <i>Canadian Journal of Urology</i> , 2021, 28, 10620-10624.	0.0	0
231	Reply by Authors. <i>Journal of Urology</i> , 2022, , 101097JU0000000000000244302.	0.4	0